Acrivon draws in $130M; Vin­cerx Phar­ma's Ph1 metasta­t­ic tu­mor da­ta

Acrivon rais­es $130M PIPE: The pre­ci­sion on­col­o­gy biotech brought in the mon­ey from RA Cap­i­tal, Per­cep­tive Ad­vi­sors and oth­er in­vestors. Its stock $ACRV was up more than 50% in ear­ly Tues­day trad­ing. — Kyle LaHu­cik

Vin­cerx Phar­ma’s Ph1 metasta­t­ic tu­mor da­ta dis­ap­points in­vestors: The com­pa­ny’s VIP236 was well-tol­er­at­ed with no dose-lim­it­ing tox­i­c­i­ties when giv­en once every three weeks, ac­cord­ing to re­sults pre­sent­ed at the Amer­i­can As­so­ci­a­tion for Can­cer Re­search’s an­nu­al meet­ing. Of the 15 pa­tients treat­ed, sev­en achieved ob­jec­tive sta­ble dis­ease, but there were no RE­CIST re­spons­es. The com­pa­ny’s stock $VINC was down about 75% on Tues­day morn­ing. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER